Juvena Therapeutics | $33,500,000 | (Jan 14, 2026)
bricks.sh | $1,863,303 | (Jan 14, 2026)
Allos | $5,000,000 | (Jan 14, 2026)
Actithera
Norway
- Oslo
- 09/07/2025
- Series A
- $75,500,000
Actithera is a radiopharmaceutical biotech company translating medicinal chemistry insights into next-generation radioligand therapies (RLTs). Founded in 2021 by drug discovery innovator Dr. Andreas Goutopoulos, and seed investors M Ventures, and Arkin Bio Ventures II, Actithera applies various molecular design strategies, including covalent-targeting and an isotope-agnostic philosophy to invent RLTs with significant differentiation and larger therapeutic windows. Headquartered in Oslo, Norway, and Cambridge, Massachusetts, Actithera is committed to advancing a differentiated pipeline addressing critical unmet needs in oncology.
- Industry Biotechnology Research
- Website https://actithera.com/
- LinkedIn https://www.linkedin.com/company/actithera/
Related People
Andreas GoutopoulosFounder
United States -
Boston, Massachusetts
Founder of Actithera, developing smarter radiopharmaceuticals to treat cancer more effectively and safely. Focused on turning chemistry and science into better outcomes for patients.
PayMedix | $33,000,000 | (Jan 14, 2026)
WeatherPromise | $12,800,000 | (Jan 14, 2026)
Diffraqtion | $4,200,000 | (Jan 14, 2026)
WithCoverage | $42,000,000 | (Jan 14, 2026)
Nodu | $1,450,000 | (Jan 14, 2026)
Cloudforce | $10,000,000 | (Jan 14, 2026)
Converge Bio | $25,000,000 | (Jan 14, 2026)
JetZero | $175,000,000 | (Jan 14, 2026)
TRYBE | $30,000,000 | (Jan 13, 2026)